Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.

Biological & pharmaceutical bulletin - 1 Aug 2017

Lou Wei, Chen Yan, Zhu Ke-Ying, Deng Huizi, Wu Tianhao, Wang Jun

Abstract excerpt

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the most important limiting factor for treatment efficiency in EGFR-mutant non-small cell lung cancer (NSCLC). Much work has linked the epithelial-mesenchymal transition (EMT) to the emergence of drug resistance, consequently, ongoing research has been focused on exploring the therapeutic options to reverse EMT for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Erlotinib Hydrochloride

Share to Interleukin-6

Share to Mice, Nude

Share to STAT3 Transcription Factor

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28515374
DOI: 10.1248/bpb.b17-00271

Genes

EGFR
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.PMID 28515374Read ↗

Epithelial to Mesenchymal Transition in Lung Cancer: Potential EMT-Targeting Natural Product-derived CompoundsSemantic proximity Read ↗

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.Semantic proximity Read ↗

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.Semantic proximity Read ↗

Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathwaysSemantic proximity Read ↗

Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug CombinationSemantic proximity Read ↗

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.Semantic proximity Read ↗

Traditional Chinese Medicine reverses resistance to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer: a narrative review.Semantic proximity Read ↗

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.Semantic proximity Read ↗

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway.Semantic proximity Read ↗

Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.Semantic proximity Read ↗

Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.